Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

DTB review ezetimibe

The Drugs and Therapeutics Bulletin has published a review of the evidence for ezetimibe in order to identify a place in therapy for this drug.

The review considers new efficacy and safety data that has been published since the first review in 2004. In particular the review considers the concerns raised linking ezetimibe with cancer that arose following publication of the SEAS Study.

The review notes that trials conducted with patient orientated clinical outcomes have so far failed to prove a benefit. It is therefore recommended that in patients with cardiovascular disease or in those at risk of developing it, "every effort should be made to reduce LDL-cholesterol with a statin alone". Additionally, use of the combination product (Inegy®) is discouraged based on the premium price for the single tablet.

Action: Clinicians should be aware of this review and National guidance for lipid modification. Ezetimibe is useful in cases of genuine statin intolerance or when treatment targets cannot be reached with optimal statin therapy.

Share 'DTB review ezetimibe' on Email Share 'DTB review ezetimibe' on Delicious Share 'DTB review ezetimibe' on Digg Share 'DTB review ezetimibe' on Facebook Share 'DTB review ezetimibe' on Google+ Share 'DTB review ezetimibe' on reddit Share 'DTB review ezetimibe' on StumbleUpon Share 'DTB review ezetimibe' on Twitter

atomic-wealth

One Comments to “DTB review ezetimibe”

  1. Not quite what NICE said in TA132.....

    Comment by Andrew Martin — August 12, 2009 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,518 spam comments.

atomic-wealth
fond-illness
summer